Continuation of Type 1 Diabetes in Acute Pancreatitis Consortium – UF Health and AdventHealth Combined Clinical Center

University Of Florida, Gainesville FL

Investigators

Linked publications, trials & patents

Abstract

The objective of this University of Florida/Advent Health proposal within the Type 1 Diabetes in Acute Pancreatitis Consortium (T1DAPC) is to continue to establish and follow a longitudinal prospective cohort of patients with acute and acute relapsing pancreatitis to investigate the incidence, pathophysiology, mechanisms, environmental and biologic risk factors, and predictors of subsequent diabetes. The Diabetes Institute at UF (UFDI) and the Advent Health Translational Research Institute have the resources and capabilities required to continue to recruit these patients and perform comprehensive genetic, immunologic, metabolic, histologic, and functional testing to dissect the various mechanisms underlying diabetes following acute pancreatitis. Our proposal addresses key ongoing needs of the T1DAPC. 1) A platform for continuing to recruit and follow large numbers of subjects with acute or acute relapsing pancreatitis. The combined volumes of both health systems approach 2,000 patients admitted with acute pancreatitis yearly. The clinical expertise and existing clinical research support structure is experienced and capable, and the two Institutes have the scientific expertise to help define and support the whole variety of mechanistic studies that are ongoing; 2) The development of an ancillary study (DREAM-ON) for which funding was obtained in an R01 (Rich Pratley, MD, AdventHealth), and which is now launching. This will supplement the mechanistic studies of diabetes after acute pancreatitis which are ongoing across the consortium; 3) A consortium opportunity to characterize the mechanisms of diabetes across the spectrum of pancreatitis using both tissue and biologic specimens (our Aim 2). Collecting a bank of human pancreata from subjects with previous pancreatitis forms part of this proposal, using the Network for Pancreatic Organ donors with Diabetes (nPOD), housed at the UF Diabetes Institute, which collects and processes transplant-grade pancreata and other tissues from organ procurement organizations (OPOs) across the U.S. and provides them for investigators around the world. We will leverage this infrastructure, along with that of a large local OPO associated with AdventHealth, to obtain organs from individuals with a history of acute pancreatitis. This will provide a unique resource for the T1DAPC, to interrogate the mechanisms of diabetes in tissue, which is not readily accessible in living subjects. This can provide a clinicopathologic correlation for the T1DAPC mechanistic studies. We believe the types of analyses proposed will be necessary for the work of the T1DAPC, and we are able to fully support these aims or related aims selected by the T1DAPC.